Flavopiridol inhibits lipopolysaccharide-induced TNF-α production through inactivation of nuclear factor-κB and mitogen-activated protein kinases in the MyD88-dependent pathway

Microbiology and Immunology

Volumn 55, Issue 3, 2011, Pages 160-167

  Haque, Abedul ^a   Koide, Naoki ^a   Iftakhar E Khuda, Imtiaz ^a   Noman, Abu Shadat Mohammod ^a   Odkhuu, Erdenezaya ^a   Badamtseren, Battuvshin ^a   Naiki, Yoshikazu ^a   Komatsu, Takayuki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Flavopiridol; Lipopolysaccharide; Mitogen activated protein kinase; Nitric oxide; Nuclear factor B; Tumor necrosis factor

Indexed keywords

CD14 ANTIGEN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FLAVOPIRIDOL; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIGENS, CD14; CELL LINE; FLAVONOIDS; GENE EXPRESSION REGULATION, ARCHAEAL; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; NITRIC OXIDE; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951961119     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2010.00304.x     Document Type: Article

References (31)

1. Takada Y., Sethi G., Sung B., Aggarwal B.B. (2008) Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Mol Pharmacol 73: 1549-57.
2. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-78.
3. Takada Y., Aggarwal B.B. (2004) Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279: 4750-59.
4. Arguello F., Alexander M., Sterry J.A., Tudor G., Smith E.M., Kalavar N.T., Greene J.F. Jr., Koss W., Morgan C.D., Stinson S.F., Siford T.J., Alvord W.G., Klabansky R.L., Sausville E.A. (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91: 2482-90.
5. Karp J.E., Ross D.D., Yang W., Tidwell M.L., Wei Y., Greer J., Mann D.L., Nakanishi T., Wright J.J., Colevas A.D. (2003) Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res 9: 307-15.
6. Morris D.G., Bramwell V.H., Turcotte R., Figueredo A.T., Blackstein M.E., Verma S., Matthews S., Eisenhauer E.A. (2006) A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006: 1-7.
7. Fornier M.N., Rathkopf D., Shah M., Patil S., O'Reilly E., Tse A.N., Hudis C., Lefkowitz R., Kelsen D.P., Schwartz G.K. (2007) Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 13: 5841-46.
8. Baeuerle P.A., Baichwal V.R. (1997) NF-kappaB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 65: 111-37.
9. Akira S., Yamamoto M., Takeda K. (2003) Role of adapters in Toll-like receptor signaling. Biochem Soc Trans 31: 637-42.
10. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126: 131-38.
11. Khuda I.I., Koide N., Noman A.S., Dagvadorj J., Tumurkhuu G., Naiki Y., Komatsu T., Yoshida T., Yokochi T. (2009) Astrocyte elevated gene-1 (AEG-1) is induced by lipopolysaccharide as toll-like receptor 4 (TLR4) ligand and regulates TLR4 signaling. Immunology 128: 700-06.
12. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. (1997) The IκB kinase complex (IKK) contains two kinase subunits, IKKα and β, necessary for IκB phosphorylation and NF-κB activation. Cell 91: 243-52.
13. Saklatvala J., Davis W., Guesdon F. (1996) Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Philos Trans R Soc Lond B Biol Sci 351: 151-57.
14. Han J., Lee J.D., Bibbs L., Ulevitch R.J. (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-11.
15. Hambleton J., Weinstein S.L., Lem L., DeFranco A.L. (1996) Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA 93: 2774-78.
16. Yamamoto M., Sato S., Hemmi H., Uematsu S., Hoshino K., Kaisho T., Takeuchi O., Takeda K., Akira S. (2003) TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4: 1144-50.
17. Cao Z., Xiong J., Takeuchi M., Kurama T., Goeddel D.V. (1996) TRAF6 is a signal transducer for interleukin-1. Nature 383: 443-46.
18. Laird M.H., Rhee S.H., Perkins D.J., Medvedev A.E., Piao W., Fenton M.J., Vogel S.N. (2009) TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 85: 966-77.
19. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., Le J., Koh S.I., Kimura T., Green S.J., et al (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-15.
20. Perrella M.A., Patterson C., Tan L., Yet S.F., Hsieh C.M., Yoshizumi M., Lee M.E. (1996) Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta1 in vascular smooth muscle cells. Evidence for mechanisms other than NF-kappaB. J Biol Chem 271: 13776-80.
21. Song H.Y., Regnier C.H., Kirschning C.J., Goeddel D.V., Rothe M. (1997) Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 94: 9792-96.
22. Yuasa T., Ohno S., Kehrl J.H., Kyriakis J.M. (1998) Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38. J Biol Chem 273: 22681-92.
23. O' Neill L.A., Bowie A.G. (2007) The family of five: TIR-domain containing adaptors in Toll-like receptor signaling. Nat Rev Immunol 7: 353-64.
24. Johnson A.C., Li X., Pearlman E. (2008) MyD88 functions as a negative regulator of TLR3/TRIF-induced corneal inflammation by inhibiting activation of c-Jun N-terminal kinase. J Biol Chem 283: 3988-96.
25. Kawai T., Takeuchi O., Fujita T., Inoue J., Muhlradt P.F., Sato S., Hoshino K., Akira S. (2001) Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes1. J Immunol 167: 5887-94.
26. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., Akira S. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-43.
27. Esposito E., Cuzzocrea S. (2009) TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 16: 3152-67.
28. Sharma J.N., Al-Omran A., Parvathy S.S. (2007) Role of nitric oxide in inflammatory diseases. Inflammopharmacol 15: 252-59.
29. Ahn Y.M., Vogeti L., Liu C.J., Santhapuram H.K., White J.M., Vasandani V., Mitscher L.A., Lushington G.H., Hanson P.R., Powell D.R., Himes R.H., Roby K.F., Ye Q., Georg G.I. (2007) Design, synthesis, antiproliferative and CDK2-cyclin A inhibitory activity of novel flavopiridol analogues. Bioorg Med Chem 15: 702-13.
30. Manjeet K.R, Ghosh B. (1999) Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-α production in murine macrophages. Int J Immunopharmacol 21: 435-43.
31. Mu M.M., Chakravortty D., Sugiyama T., Koide N., Takahashi K., Mori I., Yoshida T., Yokochi T. (2001) The inhibitory action of quercetin on lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells. J Endotoxin Res 7: 431-38.